MedPath

Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women with Trauma-related Conditions

Not Applicable
Recruiting
Conditions
Substance Use
Interventions
Behavioral: Integrated Intervention to Promote PrEP Uptake
Other: Standard Treatment Condition
Registration Number
NCT06558825
Lead Sponsor
The University of Texas Health Science Center, Houston
Brief Summary

The investigators have previously developed an integrated bio-behavioral intervention to promote PrEP uptake and adherence in cisgender women who are undergoing treatment for trauma-related mental health conditions and who are at a higher risk for HIV. The intervention is delivered within the mental health treatment setting and integrates knowledge, behavioral skills, and motivation to engage in and adhere to PrEP care. The purpose of this study is to assess the preliminary efficacy, feasibility, and acceptability of this intervention. The hypothesis is that, compared to standard treatment, the intervention will be feasible, acceptable, and associated with greater PrEP uptake and adherence.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Currently undergoing mental health treatment;
  • Have a history of trauma;
  • HIV negative;
  • Sexually active with an opposite sex partner within the past 6 months;
  • Not using PrEP for HIV prevention at the time of screening;
  • Eligible for PrEP based on having at least one Centers for Disease Control and Prevention (CDC)-defined criteria for PrEP;
  • Fluent in English;
  • Own or have regular access to a smart phone.
Exclusion Criteria
  • HIV positive;
  • Concurrently participating in another HIV prevention program;
  • Have severe cognitive impairment that would interfere with their ability to consent, understand study procedures and/or effectively participate in therapy;
  • Have psychological distress that would prohibit them from participating in the study;
  • Be unable or unwilling to meet study requirements.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Integrated Intervention to Promote PrEP UptakeIntegrated Intervention to Promote PrEP Uptake-
Standard Treatment ConditionStandard Treatment Condition-
Primary Outcome Measures
NameTimeMethod
Number of participants who uptake PrEP12 weeks post intervention

PrEP uptake is defined as obtaining a prescription and taking the first dose.

Secondary Outcome Measures
NameTimeMethod
Change in PrEP knowledge as assessed by PrEP Knowledge Questionnairebaseline, 15 weeks post enrollment

Total score ranges from 0 to 6, with a higher score indicating a greater knowledge about PrEP.

Number of Participants who adhere to PrEP12 weeks post PrEP initiation

PrEP adherence is lab confirmed and is defined as having adequate levels of tenofovir (TFV) (\>1000ng/ml).

PrEP adherence as assessed by proportion of videos uploadedfrom the time of PrEP initiation to 12 weeks post PrEP initiation

In the intervention arm, participants are asked to take a video of themselves taking PrEP. Videos are uploaded through an app, which is offered in the intervention arm only (and not the standard treatment arm). Data will be reported as the number of days a video is uploaded divided by the number of days of the intervention period.

Intervention feasibility as assessed by study retention15 weeks post enrollment

Study retention is assessed by the the number of participants who completed the study.

Intervention feasibility as assessed by number of participants enrolledat the time of enrollment

The number enrolled is the number of participants who signed the consent form.

Change in PrEP Anticipated Stigma as assessed by the PrEP Anticipated Stigma Scalebaseline, 15 weeks post enrollment

Total score ranges from 8 to 32, with a higher score indicating greater stigma.

PrEP adherence as assessed by proportion of self-reported daily adherencefrom the time of PrEP initiation to 12 weeks post PrEP initiation

In both arms, participants are sent a questionnaires weekly in which they record the number of days they took PrEP over the past seven days. Data will be reported as the number of days PrEP is taken divided by the number of days of the intervention period.

Intervention feasibility as assessed by number of sessions attended by participants15 weeks post enrollment
Change in PrEP attitudes as assessed by PrEP Attitudes Measurebaseline, 15 weeks post enrollment

Total score ranges from 5.2 to 26, with a higher score indicating a better attitude toward PrEP.

Change in perceived HIV risk as assessed by Perceived Risk of HIV Scalebaseline, 15 weeks post enrollment

Total score ranges from 10 to 40, with a higher score indicating a greater perceived HIV risk.

Intervention acceptability as assessed by score on a satisfaction questionnaire15 weeks post enrollment

This is a 15 item questionnaire and each item is scored from 1 (not at all true) to 9 (absolutely true). Total score ranges from 15 to 135, with a higher score indicating greater satisfaction.

Trial Locations

Locations (1)

Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath